Skip to main content

Advertisement

Table 1 Characteristics that were used the analysis: all patients (Entire cohort) and split by training and testing datasetsa

From: Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records

Covariate Level Entire cohort Training cohort Test cohort
n   30,961 23,275 7686
Sex (male) n (%) 16,885 (54.54) 12,723 (54.66) 4163 (54.15)
BMI <  18.5 1305 (4.21) 978 (4.2) 327 (4.25)
≥ 18.5, <  25 9926 (32.06) 7461 (32.06) 2465 (32.07)
≥ 25, <  30 10,358 (33.45) 7758 (33.33) 2600 (33.83)
≥ 30 9372 (30.27) 7078 (30.41) 2294 (29.85)
CRS n (%) 590 (1.91) 445 (1.91) 145 (1.89)
Anxiety n (%) 3123 (10.09) 2375 (10.2) 748 (9.73)
Atopy n (%) 3809 (12.3) 2868 (12.32) 941 (12.24)
Depression n (%) 3413 (11.02) 2605 (11.19) 808 (10.51)
Diabetes n (%) 5001 (16.15) 3789 (16.28) 1212 (15.77)
Eosinophils > 2% n (%) 20,363 (65.77) 15,299 (65.73) 5064 (65.89)
GERD   2759 (8.91) 2108 (9.06) 651 (8.47)
GOLD 1 8077 (26.09) 6017 (25.85) 2060 (26.8)
2 15,536 (50.18) 11,749 (50.48) 3787 (49.27)
3 6322 (20.42) 4730 (20.32) 1592 (20.71)
4 1026 (3.31) 779 (3.35) 247 (3.21)
Heart failure n (%) 4685 (15.13) 3579 (15.38) 1106 (14.39)
Hypertension n (%) 10,515 (33.96) 7906 (33.97) 2609 (33.94)
IHD n (%) 7134 (23.04) 5379 (23.11) 1755 (22.83)
Smoking ex 14,447 (46.66) 10,920 (46.92) 3527 (45.89)
current 16,514 (53.34) 12,355 (53.08) 4159 (54.11)
Therapy type none 11,621 (37.53) 8775 (37.7) 2846 (37.03)
mono 4071 (13.15) 3018 (12.97) 1053 (13.7)
dual 10,261 (33.14) 7722 (33.18) 2539 (33.03)
triple 5008 (16.18) 3760 (16.15) 1248 (16.24)
  1. aBMI Body mass index, CRS Chronic rhinosinusitis, GERD Gastroesophageal reflux disease, IHD Ischaemic heart disease, GOLD Global initiative for chronic obstructive lung disease